<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">CNS Neurosci Ther</journal-id><journal-id journal-id-type="iso-abbrev">CNS Neurosci Ther</journal-id><journal-id journal-id-type="publisher-id">cns</journal-id><journal-title-group><journal-title>CNS Neuroscience &#x00026; Therapeutics</journal-title></journal-title-group><issn pub-type="ppub">1755-5930</issn><issn pub-type="epub">1755-5949</issn><publisher><publisher-name>BlackWell Publishing Ltd</publisher-name><publisher-loc>Oxford, UK</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">23924050</article-id><article-id pub-id-type="pmc">4233957</article-id><article-id pub-id-type="doi">10.1111/cns.12158</article-id><article-categories><subj-group subj-group-type="heading"><subject>Original Articles</subject></subj-group></article-categories><title-group><article-title>A 24-Week, Randomized, Controlled Trial of Rivastigmine Patch 13.3&#x000a0;mg/24&#x000a0;h Versus 4.6&#x000a0;mg/24&#x000a0;h in Severe Alzheimer's Dementia</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Farlow</surname><given-names>Martin R</given-names></name><xref ref-type="aff" rid="au1"/></contrib><contrib contrib-type="author"><name><surname>Grossberg</surname><given-names>George T</given-names></name><xref ref-type="aff" rid="au2"/></contrib><contrib contrib-type="author"><name><surname>Sadowsky</surname><given-names>Carl H</given-names></name><xref ref-type="aff" rid="au3"/><xref ref-type="aff" rid="au4">4</xref></contrib><contrib contrib-type="author"><name><surname>Meng</surname><given-names>Xiangyi</given-names></name><xref ref-type="aff" rid="au5"/></contrib><contrib contrib-type="author"><name><surname>Somogyi</surname><given-names>Monique</given-names></name><xref ref-type="aff" rid="au5"/></contrib><aff id="au1"><label>1</label><institution>Department of Neurology, Indiana University School of Medicine</institution><addr-line>Indianapolis, IN, USA</addr-line></aff><aff id="au2"><label>2</label><institution>Department of Neurology and Psychiatry, St Louis University School of Medicine</institution><addr-line>St Louis, MO, USA</addr-line></aff><aff id="au3"><label>3</label><institution>Division of Neurology, Nova Southeastern University</institution><addr-line>Fort Lauderdale, FL, USA</addr-line></aff><aff id="au4"><label>4</label><institution>Premiere Research Institute, Palm Beach Neurology</institution><addr-line>West Palm Beach, FL, USA</addr-line></aff><aff id="au5"><label>5</label><institution>Novartis Pharmaceuticals Corporation</institution><addr-line>East Hanover, NJ, USA</addr-line></aff></contrib-group><author-notes><corresp id="cor1"><bold>Correspondence</bold>, Martin R. Farlow, M.D., Department of Neurology, Indiana University School of Medicine, Indianapolis, IN 46202, USA., Tel.: +1&#x000a0;317&#x000a0;963&#x000a0;7402;, Fax: +1&#x000a0;317&#x000a0;963&#x000a0;7533;, E-mail: <email>mfarlow@iupui.edu</email></corresp></author-notes><pub-date pub-type="ppub"><month>10</month><year>2013</year></pub-date><pub-date pub-type="epub"><day>07</day><month>8</month><year>2013</year></pub-date><volume>19</volume><issue>10</issue><fpage>745</fpage><lpage>752</lpage><history><date date-type="received"><day>10</day><month>6</month><year>2013</year></date><date date-type="rev-recd"><day>03</day><month>7</month><year>2013</year></date><date date-type="accepted"><day>04</day><month>7</month><year>2013</year></date></history><permissions><copyright-statement>&#x000a9; 2013 The Authors. CNS Neuroscience &#x00026; Therapeutics published by John Wiley &#x00026; Sons Ltd</copyright-statement><copyright-year>2013</copyright-year><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by-nc/3.0/"><license-p>This is an open access article under the terms of the Creative Commons Attribution-NonCommercial License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.</license-p></license></permissions><abstract><sec><title>Aims</title><p>The 24-week, prospective, randomized, double-blind ACTION study investigated the efficacy, safety, and tolerability of 13.3 versus 4.6&#x000a0;mg/24&#x000a0;h rivastigmine patch in patients with severe Alzheimer's disease (AD).</p></sec><sec><title>Methods</title><p>Patients had probable AD and Mini&#x02013;Mental State Examination scores &#x02265;3&#x02013;&#x02264;12. Primary outcome measures were as follows: Severe Impairment Battery (SIB) and AD Cooperative Study&#x02013;Activities of Daily Living scale&#x02013;Severe Impairment Version (ADCS-ADL-SIV). Secondary outcomes were as follows: ADCS-Clinical Global Impression of Change (ADCS-CGIC), 12-item Neuropsychiatric Inventory (NPI-12), and safety/tolerability.</p></sec><sec><title>Results</title><p>Of 1014 patients screened, 716 were randomized to 13.3&#x000a0;mg/24&#x000a0;h (N&#x000a0;=&#x000a0;356) or 4.6&#x000a0;mg/24&#x000a0;h (N&#x000a0;=&#x000a0;360) patch. Baseline characteristics/demographics were comparable. Completion rates were as follows: 64.3% (N&#x000a0;=&#x000a0;229) with 13.3&#x000a0;mg/24&#x000a0;h and 65.0% (N&#x000a0;=&#x000a0;234) with 4.6&#x000a0;mg/24&#x000a0;h patch. The 13.3&#x000a0;mg/24&#x000a0;h patch was significantly superior to 4.6&#x000a0;mg/24&#x000a0;h patch on cognition (SIB) and function (ADCS-ADL-SIV) at Week 16 (<italic>P&#x000a0;</italic>&#x0003c;<italic>&#x000a0;</italic>0.0001 and <italic>P&#x000a0;</italic>=<italic>&#x000a0;</italic>0.049, respectively) and 24 (primary endpoint; <italic>P</italic>&#x000a0;&#x0003c;&#x000a0;0.0001 and <italic>P</italic>&#x000a0;=&#x000a0;0.025). Significant between-group differences (Week 24) were observed on the ADCS-CGIC (<italic>P</italic>&#x000a0;=&#x000a0;0.0023), not NPI-12 (<italic>P</italic>&#x000a0;=&#x000a0;0.1437). A similar proportion of the 13.3&#x000a0;mg/24&#x000a0;h and 4.6&#x000a0;mg/24&#x000a0;h patch groups reported adverse events (AEs; 74.6% and 73.3%, respectively) and serious AEs (14.9% and 13.6%).</p></sec><sec><title>Conclusions</title><p>The 13.3&#x000a0;mg/24&#x000a0;h patch demonstrated superior efficacy to 4.6&#x000a0;mg/24&#x000a0;h patch on SIB and ADCS-ADL-SIV, without marked increase in AEs, suggesting higher-dose patch has a favorable benefit-to-risk profile in severe AD.</p></sec></abstract><kwd-group><kwd>Clinical trial</kwd><kwd>Rivastigmine</kwd><kwd>Severe Alzheimer's disease</kwd><kwd>Transdermal patch</kwd></kwd-group></article-meta></front><body><sec sec-type="intro"><title>Introduction</title><p>As patients with Alzheimer's disease (AD) progress to severe stages, there is further degeneration of cortically projecting cholinergic neurons and changes in brain cholinesterase levels <xref rid="b1" ref-type="bibr">1</xref> associated with progressive impairments in memory, cognition, behavior, and performance of activities of daily living (ADL).</p><p>Cholinesterase inhibitors partially compensate for cholinergic deficits, providing symptomatic relief. Three cholinesterase inhibitors are widely approved for mild-to-moderate AD; rivastigmine (Exelon&#x000ae;, Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA), donepezil (ARICEPT&#x000ae;, Eisai Inc., Woodcliff Lake, NJ, USA), and galantamine (Razadyne&#x000ae;, Janssen Pharmaceutical N.V., Beerse, Belgium) <xref rid="b2" ref-type="bibr">2</xref>&#x02013;<xref rid="b5" ref-type="bibr">5</xref>. Until recently, treatment options for severe AD were limited; donepezil is indicated for moderate-to-severe AD in the USA <xref rid="b4" ref-type="bibr">4</xref> and memantine (N-methyl-D-aspartate receptor antagonist) for moderate-to-severe AD in the USA and several other countries worldwide <xref rid="b6" ref-type="bibr">6</xref>.</p><p>Rivastigmine shows dose-dependent efficacy on cognition, ADL, and global functioning <xref rid="b7" ref-type="bibr">7</xref>,<xref rid="b8" ref-type="bibr">8</xref>. The OPTIMA (<italic>OP</italic>timising <italic>T</italic>ransdermal Exelon <italic>I</italic>n <italic>M</italic>ild-to-moderate <italic>A</italic>D) study demonstrated significantly greater efficacy on ADL with 13.3&#x000a0;mg/24&#x000a0;h (15&#x000a0;cm<sup>2</sup>) versus 9.5&#x000a0;mg/24&#x000a0;h (10&#x000a0;cm<sup>2</sup>) rivastigmine patch in patients with mild-to-moderate AD who showed functional and cognitive decline during preceding open-label treatment with 9.5&#x000a0;mg/24&#x000a0;h patch <xref rid="b9" ref-type="bibr">9</xref>.</p><p>Pooled analysis of clinical trial data suggests rivastigmine may continue to provide benefits at more advanced stages of disease <xref rid="b10" ref-type="bibr">10</xref>,<xref rid="b11" ref-type="bibr">11</xref>. A randomized, double-blind, study demonstrated that oral rivastigmine was efficacious compared with placebo in moderately severe AD <xref rid="b12" ref-type="bibr">12</xref>.</p><p>The objective of the ACTION (<italic>ACT</italic>ivities of daily living and cognit<italic>ION</italic>) study was to compare the efficacy, safety, and tolerability of 13.3&#x000a0;mg/24&#x000a0;h (15&#x000a0;cm<sup>2</sup>) versus 4.6&#x000a0;mg/24&#x000a0;h (5&#x000a0;cm<sup>2</sup>) rivastigmine patch in patients with severe AD.</p></sec><sec sec-type="materials|methods"><title>Materials and Methods</title><sec><title>Patients</title><p>Patients were male/female, aged &#x02265;50&#x000a0;years, with probable AD (original 1984 National Institute of Neurological and Communicative Disorders and Stroke and AD and Related Disorders Association criteria) <xref rid="b13" ref-type="bibr">13</xref>, and Mini&#x02013;Mental State Examination (MMSE) <xref rid="b14" ref-type="bibr">14</xref> scores &#x02265;3&#x02013;&#x02264;12. Magnetic resonance imaging/computed tomography, used in the diagnosis of probable AD, was required within the prior 2&#x000a0;years. Patients were living with someone in the community or were in regular contact with their primary caregiver. Patients in assisted living facilities were eligible provided assessment could take place at the study site, and a caregiver was identified <xref rid="b15" ref-type="bibr">15</xref>.</p><p>Exclusion criteria included any advanced/severe/progressive/unstable disease that could interfere with response to study treatment; patients living in/permanently placed during the study/likely (physicians' opinion) to be placed in a nursing home within the next 7&#x000a0;months; current medical/neurological condition other than AD that could be the primary cause of dementia; current diagnosis of probable/possible vascular dementia, uncontrolled seizure disorder, severe/unstable cardiovascular disease, bradycardia, sick-sinus syndrome or conduction defects; current diagnosis of acute/severe/unstable asthmatic conditions; current diagnosis of uncontrolled peptic ulceration or gastrointestinal bleeding within the previous 3&#x000a0;months; and/or a history (past year) or current diagnosis of cerebrovascular disease. Patients were also excluded if they had a Diagnostic and Statistical Manual of Mental Disorders diagnosis of major depression <xref rid="b16" ref-type="bibr">16</xref>, unless successfully treated (antidepressant without anticholinergic properties) in a stable regimen for &#x02265;4&#x000a0;weeks; clinically significant urinary obstruction; allergy to vitamin E-containing products, sensitivity to cholinergic drugs, or skin lesion/disorder that would prevent patch use; history of malignancy (&#x02264;5&#x000a0;years); use of cholinesterase inhibitors/other approved AD treatments 2&#x000a0;weeks prior (except stable memantine if taken for &#x02265;3&#x000a0;months); use of centrally acting cholinergic drugs/any investigational drug for 4&#x000a0;weeks prior; use of peripheral anticholinergic drugs/selegiline, or new psychotropic/dopaminergic drugs if not taken at stable dose, for 4&#x000a0;weeks prior <xref rid="b15" ref-type="bibr">15</xref>.</p></sec><sec><title>Standard Protocol Approvals, Registrations, and Patient Consents</title><p>The protocol and amendments were reviewed by Independent Ethics Committees or Institutional Review Boards. The study was conducted in accordance with Good Clinical Practice and the ethical principles of the Declaration of Helsinki. All patients, or if they lacked capacity, their legally authorized representative, provided written informed consent prior to participating. This study is registered (clinicaltrials.gov NCT00948766).</p><p>Protocol amendments after study-start included clarifying enrollment eligibility requirements and revising instructions for patch application to prevent administration errors.</p></sec><sec><title>Study Design</title><p>ACTION was a 24-week, prospective, randomized, double-blind, double-dummy, multicenter trial conducted at 82 centers across the USA between July 22, 2009 and January 10, 2012 (last-patient-last-visit). Patients were randomized (1:1) at Week 0 to 13.3&#x000a0;mg/24&#x000a0;h or 4.6&#x000a0;mg/24&#x000a0;h rivastigmine patch. All patients initiated treatment on 4.6&#x000a0;mg/24&#x000a0;h patch. Patients randomized to 13.3&#x000a0;mg/24&#x000a0;h patch were up-titrated (start of Week 4) to 9.5&#x000a0;mg/24&#x000a0;h patch and at the start of Week 8 to 13.3&#x000a0;mg/24&#x000a0;h patch. Patients randomized to 4.6&#x000a0;mg/24&#x000a0;h patch remained at that dose for the 8-week titration. Patients were maintained at the target dose for the 16-week maintenance period <xref rid="b15" ref-type="bibr">15</xref>. The 4.6&#x000a0;mg/24&#x000a0;h patch group also received 10&#x000a0;cm<sup>2</sup> (from start of Week 4) and 15&#x000a0;cm<sup>2</sup> placebo patches (from start of Week 8&#x02013;24). The 13.3&#x000a0;mg/24&#x000a0;h patch group received 5&#x000a0;cm<sup>2</sup> placebo patches throughout.</p><p>For patients missing &#x0003e;3 consecutive days of treatment due to tolerability problems, treatment could be restarted (4.6&#x000a0;mg/24&#x000a0;h) and the dose increased after 2&#x000a0;weeks minimum. If tolerability was improved and the patient had missed treatment for &#x02264;3 consecutive days, treatment could be restarted at the same dose level, and titration resumed. Further doses could be skipped if subsequent titration led to tolerability problems. In the maintenance phase, patients were required to be able to tolerate the maximum dose and were not permitted to down-titrate, so as not to compromise blinding.</p></sec><sec><title>Primary Outcomes</title><p>Primary outcomes were the change from baseline&#x02013;Week 24 on the Severe Impairment Battery (SIB) <xref rid="b17" ref-type="bibr">17</xref> and AD Cooperative Study&#x02013;ADL scale&#x02013;Severe Impairment Version (ADCS-ADL-SIV) <xref rid="b18" ref-type="bibr">18</xref>.</p></sec><sec><title>Secondary Outcomes</title><p>Secondary outcomes were as follows: ADCS&#x02013;Clinical Global Impression of Change (ADCS-CGIC) <xref rid="b19" ref-type="bibr">19</xref> score at Week 24, and the change from baseline&#x02013;Week 24 on the 12-item Neuropsychiatric Inventory (NPI-12) <xref rid="b20" ref-type="bibr">20</xref>.</p><p>In addition to Week 24 (primary endpoint), all efficacy measures were assessed at Weeks 8 and 16.</p><p>Evaluations to maintain safety included the following: incidence of adverse events (AEs) and serious AEs (SAEs); laboratory tests; electrocardiogram analysis; assessments of skin irritation and vital signs; and the discontinuation rate due to AEs.</p></sec><sec><title>Sample Size, Randomization, and Blinding</title><p>It was estimated that 338 patients were required/group to achieve an effect size of 0.25 on the primary efficacy variables and overall power between 82% and 85%, assuming a correlation coefficient between the co-primary efficacy variables of 0.3&#x02013;0.6. To adjust for the 5% of patients estimated to be lost to follow-up, a total sample size of 712 was planned.</p><p>Centralized block randomization was performed by an interactive voice response system. The investigator/his/her delegate was required to contact the interactive voice response system and confirm patient eligibility. The interactive voice response system assigned a randomization number, linking the patient to a treatment arm, and specified a unique medication number to dispense the first package of study medication. The randomization scheme was reviewed and approved by the Novartis Biostatistics Quality Assurance Group.</p><p>Patients, study investigators, and data analysts remained blinded from randomization until database lock. Unblinding occurred only in case of patient emergencies and at study end.</p></sec><sec><title>Statistical Analyses</title><p>The null hypotheses were 13.3&#x000a0;mg/24&#x000a0;h would not differ from 4.6&#x000a0;mg/24&#x000a0;h patch in the change from baseline&#x02013;Week 24 on ADCS-ADL-SIV/SIB total score. The alternative was 13.3&#x000a0;mg/24&#x000a0;h differs from 4.6&#x000a0;mg/24&#x000a0;h patch in change from baseline&#x02013;Week 24 in ADCS-ADL-SIV and SIB total score. Significant efficacy on both primary outcomes was required to demonstrate superiority of 13.3&#x000a0;mg/24&#x000a0;h over 4.6&#x000a0;mg/24&#x000a0;h patch.</p><p>Analyses of primary outcomes were based on the modified full analysis set (all randomized patients who received &#x02265;1 dose of study medication and had &#x02265;1 postbaseline measurement). Imputation of missing values was performed following the last-observation-carried-forward approach. Treatment differences in the change from baseline on the ADCS-ADL-SIV, SIB, and NPI-12 were compared using least-squares means derived using analysis of covariance (ANCOVA) with treatment and pooled center as factors and corresponding baseline score as a covariate. ADCS-CGIC scores were analyzed using the Cochran&#x02013;Mantel&#x02013;Haenszel test, with modification relative to an identified distribution integral transformation scores adjusting for pooled center.</p><p>Longitudinal analysis of the change from baseline for the co-primary efficacy variables was performed for the modified full analysis set using observed cases. An unstructured covariance matrix for the repeated measures within each patient was applied. Explanatory variables included treatment, pooled center, week, treatment-by-week, and corresponding baseline. Treatment groups were compared based on least-squares means. The SAS procedure PROC MIXED was used.</p><p>Sensitivity analyses were conducted using a pattern mixture model considering missing data (completers and noncompleters) for each co-primary efficacy variable and were based on a repeated-measures ANCOVA model with treatment, pooled center, week, dropout, treatment-by-week, treatment-by-dropout as factors, and baseline as a covariate, assuming an unstructured within-subject covariance matrix.</p><p>Safety analyses were based on the safety set (all patients who received &#x02265;1 dose of study medication and had &#x02265;1 safety assessment postbaseline) and were summarized according to treatment received.</p><p>For continuous variables, number of patients with observed values (n), mean, standard deviation (SD), 95% confidence intervals (95% CI), minimum, and maximum were calculated. Categorical variables were summarized by frequency counts and percentages. Unless otherwise specified, all statistical tests were conducted against a two-sided alternative hypothesis; <italic>P</italic>-values below 0.05 were considered significant.</p></sec></sec><sec sec-type="results"><title>Results</title><sec><title>Study Participants</title><p>Of 1014 patients screened, 716 were enrolled and randomized to 13.3&#x000a0;mg/24&#x000a0;h (N&#x000a0;=&#x000a0;356) or 4.6&#x000a0;mg/24&#x000a0;h rivastigmine patch (N&#x000a0;=&#x000a0;360). Similar proportions of each group completed the study (<xref ref-type="fig" rid="fig01">Figure 1</xref>). Baseline demographics and characteristics were comparable (<xref ref-type="table" rid="tbl1">Table 1</xref>).</p><table-wrap id="tbl1" position="float"><label>Table 1</label><caption><p>Patient demographics and background characteristics by treatment group (randomized set)</p></caption><table frame="hsides" rules="groups"><thead><tr><th rowspan="1" colspan="1"/><th align="left" rowspan="1" colspan="1">13.3&#x000a0;mg/24&#x000a0;h rivastigmine patch</th><th align="left" rowspan="1" colspan="1">4.6&#x000a0;mg/24&#x000a0;h rivastigmine patch</th><th align="left" rowspan="1" colspan="1">Total</th></tr><tr><th align="left" rowspan="1" colspan="1">N&#x000a0;=&#x000a0;356</th><th align="left" rowspan="1" colspan="1">N&#x000a0;=&#x000a0;360</th><th align="left" rowspan="1" colspan="1">N&#x000a0;=&#x000a0;716</th></tr></thead><tbody><tr><td align="left" colspan="4" rowspan="1">Age, years</td></tr><tr><td align="left" rowspan="1" colspan="1">Mean (SD)</td><td align="left" rowspan="1" colspan="1">77.6 (8.7)</td><td align="left" rowspan="1" colspan="1">76.5 (9.4)</td><td align="left" rowspan="1" colspan="1">77.0 (9.0)</td></tr><tr><td align="left" rowspan="1" colspan="1">Range</td><td align="left" rowspan="1" colspan="1">52&#x02013;96</td><td align="left" rowspan="1" colspan="1">51&#x02013;96</td><td align="left" rowspan="1" colspan="1">51&#x02013;96</td></tr><tr><td align="left" colspan="4" rowspan="1">Gender, %</td></tr><tr><td align="left" rowspan="1" colspan="1">Female</td><td align="left" rowspan="1" colspan="1">63.8</td><td align="left" rowspan="1" colspan="1">65.0</td><td align="left" rowspan="1" colspan="1">64.4</td></tr><tr><td align="left" colspan="4" rowspan="1">Predominant race, %</td></tr><tr><td align="left" rowspan="1" colspan="1">Caucasian</td><td align="left" rowspan="1" colspan="1">86.0</td><td align="left" rowspan="1" colspan="1">88.6</td><td align="left" rowspan="1" colspan="1">87.3</td></tr><tr><td align="left" rowspan="1" colspan="1">Black</td><td align="left" rowspan="1" colspan="1">7.9</td><td align="left" rowspan="1" colspan="1">5.3</td><td align="left" rowspan="1" colspan="1">6.6</td></tr><tr><td align="left" rowspan="1" colspan="1">Other</td><td align="left" rowspan="1" colspan="1">6.2</td><td align="left" rowspan="1" colspan="1">6.1</td><td align="left" rowspan="1" colspan="1">6.2</td></tr><tr><td align="left" colspan="4" rowspan="1">MMSE score</td></tr><tr><td align="left" rowspan="1" colspan="1">Mean (SD)</td><td align="left" rowspan="1" colspan="1">8.8 (2.9)</td><td align="left" rowspan="1" colspan="1">8.8 (3.0)</td><td align="left" rowspan="1" colspan="1">8.8 (2.9)</td></tr><tr><td align="left" rowspan="1" colspan="1">Range</td><td align="left" rowspan="1" colspan="1">3.0&#x02013;13.0</td><td align="left" rowspan="1" colspan="1">3.0&#x02013;19.0</td><td align="left" rowspan="1" colspan="1">3.0&#x02013;19.0</td></tr><tr><td align="left" colspan="4" rowspan="1">Years since diagnosis of AD</td></tr><tr><td align="left" rowspan="1" colspan="1">Mean (SD)</td><td align="left" rowspan="1" colspan="1">4.3 (2.7)</td><td align="left" rowspan="1" colspan="1">4.0 (2.7)</td><td align="left" rowspan="1" colspan="1">4.1 (2.7)</td></tr><tr><td align="left" rowspan="1" colspan="1">Range</td><td align="left" rowspan="1" colspan="1">0.0&#x02013;19.1</td><td align="left" rowspan="1" colspan="1">0.0&#x02013;18.3</td><td align="left" rowspan="1" colspan="1">0.0&#x02013;19.1</td></tr><tr><td align="left" colspan="4" rowspan="1">Years since diagnosis of severe dementia</td></tr><tr><td align="left" rowspan="1" colspan="1">Mean (SD)</td><td align="left" rowspan="1" colspan="1">1.2 (1.9)</td><td align="left" rowspan="1" colspan="1">1.2 (1.6)</td><td align="left" rowspan="1" colspan="1">1.2 (1.7)</td></tr><tr><td align="left" rowspan="1" colspan="1">Range</td><td align="left" rowspan="1" colspan="1">0.0&#x02013;12.2</td><td align="left" rowspan="1" colspan="1">0.0&#x02013;9.8</td><td align="left" rowspan="1" colspan="1">0.0&#x02013;12.2</td></tr><tr><td align="left" colspan="4" rowspan="1">Patients living situation, %</td></tr><tr><td align="left" rowspan="1" colspan="1">Home</td><td align="left" rowspan="1" colspan="1">90.4</td><td align="left" rowspan="1" colspan="1">88.1</td><td align="left" rowspan="1" colspan="1">89.2</td></tr><tr><td align="left" rowspan="1" colspan="1">Assisted living facility</td><td align="left" rowspan="1" colspan="1">7.6</td><td align="left" rowspan="1" colspan="1">9.7</td><td align="left" rowspan="1" colspan="1">8.7</td></tr><tr><td align="left" rowspan="1" colspan="1">Other</td><td align="left" rowspan="1" colspan="1">2.0</td><td align="left" rowspan="1" colspan="1">2.2</td><td align="left" rowspan="1" colspan="1">2.1</td></tr></tbody></table><table-wrap-foot><fn><p>AD, Alzheimer's disease; MMSE, Mini&#x02013;Mental State Examination; N, number of patients in the randomized population; SD, standard deviation.</p></fn></table-wrap-foot></table-wrap><fig id="fig01" position="float"><label>Figure 1</label><caption><p>Patient disposition throughout the study (randomized population). AEs, adverse events; N, number of patients in the population; n, number of patients with an assessment. One patient in each treatment group was randomized, but was not exposed to study medication.</p></caption><graphic xlink:href="cns0019-0745-f1"/></fig></sec><sec><title>Dosing</title><p>All patients randomized to 4.6&#x000a0;mg/24&#x000a0;h patch received this dose at Week 24. Of those patients randomized to 13.3&#x000a0;mg/24&#x000a0;h patch, 85.1% received the target dose at Week 24; 6.5% and 8.5% received 9.5&#x000a0;mg/24&#x000a0;h or 4.6&#x000a0;mg/24&#x000a0;h patch, respectively. Mean (SD) duration of exposure was 19.6 (7.9) weeks in the 13.3&#x000a0;mg/24&#x000a0;h patch group and 20.1 (7.6) weeks in the 4.6&#x000a0;mg/24&#x000a0;h patch group.</p></sec><sec><title>Concomitant Medications</title><p>Overall, 96.1% and 95.8% of the 13.3&#x000a0;mg/24&#x000a0;h and 4.6&#x000a0;mg/24&#x000a0;h patch groups, respectively, were taking concomitant medication and/or using nondrug therapies. There were no notable differences in concomitant medication use between groups; the most commonly used were platelet aggregation inhibitors (43.9%, 13.3&#x000a0;mg/24&#x000a0;h; 40.4%, 4.6&#x000a0;mg/24&#x000a0;h patch group) and 3-hydroxy-3-methyl-glutaryl-CoA reductase inhibitors (40.3% and 41.2%, respectively).</p><p>Psychotropic medications were taken by 83.9% and 82.5% of the 13.3&#x000a0;mg/24&#x000a0;h and 4.6&#x000a0;mg/24&#x000a0;h patch groups, respectively, and were most commonly antidementia drugs (primarily memantine hydrochloride; 60.6%), and selective serotonin reuptake inhibitors (38.7%).</p></sec><sec><title>Primary Outcome Analyses</title><p>SIB scores decreased from baseline in both groups throughout the study. Significantly less deterioration was observed at Weeks 16 (<italic>P</italic>&#x000a0;&#x0003c;&#x000a0;0.0001; difference 4.9 points; 95% CI 2.8, 6.9) and 24 (primary endpoint; <italic>P</italic>&#x000a0;&#x0003c;&#x000a0;0.0001; difference 4.9 points; 95% CI 2.8, 7.0) with 13.3&#x000a0;mg/24&#x000a0;h compared with 4.6&#x000a0;mg/24&#x000a0;h patch (<xref ref-type="fig" rid="fig02">Figure 2</xref>A; <xref ref-type="table" rid="tbl2">Table 2</xref>). Similar findings were observed in longitudinal (<italic>P</italic>&#x000a0;&#x0003c;&#x000a0;0.0001; difference 5.3 points; 95% CI 3.1, 7.5 at Week 16 and <italic>P</italic>&#x000a0;&#x0003c;&#x000a0;0.0001; difference 5.3 points; 95% CI 3.0, 7.7 at Week 24) and sensitivity analyses (<italic>P</italic>&#x000a0;&#x0003c;&#x000a0;0.0001; difference 6.0 points; 95% CI 3.6, 8.3 at Week 16 and <italic>P</italic>&#x000a0;&#x0003c;&#x000a0;0.0001; difference 6.1 points, 95% CI 3.6, 8.6 at Week 24).</p><table-wrap id="tbl2" position="float"><label>Table 2</label><caption><p>Primary (SIB and ADCS-ADL-SIV) and secondary (ADCS-CGIC and NPI-12) efficacy outcomes (modified full analysis set)</p></caption><table frame="hsides" rules="groups"><thead><tr><th rowspan="1" colspan="1"/><th align="left" rowspan="1" colspan="1">13.3&#x000a0;mg/24&#x000a0;h rivastigmine patch</th><th align="left" rowspan="1" colspan="1">4.6&#x000a0;mg/24&#x000a0;h rivastigmine patch</th><th align="left" rowspan="2" colspan="1"><italic>P</italic>-value</th></tr><tr><th align="left" rowspan="1" colspan="1">N&#x000a0;=&#x000a0;338</th><th align="left" rowspan="1" colspan="1">N&#x000a0;=&#x000a0;335</th></tr></thead><tbody><tr><td align="left" colspan="4" rowspan="1">SIB</td></tr><tr><td align="left" rowspan="1" colspan="1">N (baseline)</td><td align="left" rowspan="1" colspan="1">336</td><td align="left" rowspan="1" colspan="1">334</td><td rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Mean (SD) score at baseline</td><td align="left" rowspan="1" colspan="1">69.3 (21.5)</td><td align="left" rowspan="1" colspan="1">68.3 (22.8)</td><td rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">N (Week 24)</td><td align="left" rowspan="1" colspan="1">313</td><td align="left" rowspan="1" colspan="1">316</td><td rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Mean (SD) change from baseline at Week 24</td><td align="left" rowspan="1" colspan="1">&#x02212;1.6 (13.5)</td><td align="left" rowspan="1" colspan="1">&#x02212;6.4 (14.0)</td><td rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Least-squares means (SE) change from baseline at Week 24</td><td align="left" rowspan="1" colspan="1">&#x02212;1.7 (0.8)</td><td align="left" rowspan="1" colspan="1">&#x02212;6.6 (0.8)</td><td rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Least-squares means difference (95% CI)</td><td align="left" colspan="2" rowspan="1">4.9 (2.8, 7.0)</td><td align="left" rowspan="1" colspan="1">&#x0003c;0.0001</td></tr><tr><td align="left" colspan="4" rowspan="1">ADCS-ADL-SIV</td></tr><tr><td align="left" rowspan="1" colspan="1">N (baseline)</td><td align="left" rowspan="1" colspan="1">333</td><td align="left" rowspan="1" colspan="1">319</td><td rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Mean (SD) score at baseline</td><td align="left" rowspan="1" colspan="1">29.7 (11.3)</td><td align="left" rowspan="1" colspan="1">29.1 (11.9)</td><td rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">N (Week 24)</td><td align="left" rowspan="1" colspan="1">310</td><td align="left" rowspan="1" colspan="1">303</td><td rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Mean (SD) change from baseline at Week 24</td><td align="left" rowspan="1" colspan="1">&#x02212;2.6 (6.8)</td><td align="left" rowspan="1" colspan="1">&#x02212;3.6 (7.7)</td><td rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Least-squares means (SE) change from baseline at Week 24</td><td align="left" rowspan="1" colspan="1">&#x02212;2.4 (0.4)</td><td align="left" rowspan="1" colspan="1">&#x02212;3.6 (0.4)</td><td rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Least-squares means difference (95% CI)</td><td align="left" colspan="2" rowspan="1">1.2 (0.2, 2.3)</td><td align="left" rowspan="1" colspan="1">0.0247</td></tr><tr><td align="left" colspan="4" rowspan="1">ADCS-CGIC</td></tr><tr><td align="left" rowspan="1" colspan="1">Week 24, n (%)</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">0.0023</td></tr><tr><td align="left" rowspan="1" colspan="1">Marked improvement</td><td align="left" rowspan="1" colspan="1">3 (1.0)</td><td align="left" rowspan="1" colspan="1">4 (1.3)</td><td rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Moderate improvement</td><td align="left" rowspan="1" colspan="1">11 (3.5)</td><td align="left" rowspan="1" colspan="1">11 (3.5)</td><td rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Minimal improvement</td><td align="left" rowspan="1" colspan="1">63 (20.1)</td><td align="left" rowspan="1" colspan="1">36 (11.4)</td><td rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">No change</td><td align="left" rowspan="1" colspan="1">107 (34.2)</td><td align="left" rowspan="1" colspan="1">92 (29.2)</td><td rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Minimal worsening</td><td align="left" rowspan="1" colspan="1">76 (24.3)</td><td align="left" rowspan="1" colspan="1">99 (31.4)</td><td rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Moderate worsening</td><td align="left" rowspan="1" colspan="1">44 (14.1)</td><td align="left" rowspan="1" colspan="1">60 (19.0)</td><td rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Marked worsening</td><td align="left" rowspan="1" colspan="1">9 (2.9)</td><td align="left" rowspan="1" colspan="1">13 (4.1)</td><td rowspan="1" colspan="1"/></tr><tr><td align="left" colspan="4" rowspan="1">NPI-12</td></tr><tr><td align="left" rowspan="1" colspan="1">N (baseline)</td><td align="left" rowspan="1" colspan="1">335</td><td align="left" rowspan="1" colspan="1">331</td><td rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Mean (SD) score at baseline</td><td align="left" rowspan="1" colspan="1">17.3 (15.4)</td><td align="left" rowspan="1" colspan="1">16.8 (16.7)</td><td rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">N (Week 24)</td><td align="left" rowspan="1" colspan="1">313</td><td align="left" rowspan="1" colspan="1">313</td><td rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Mean (SD) change from baseline at Week 24</td><td align="left" rowspan="1" colspan="1">&#x02212;0.4 (14.0)</td><td align="left" rowspan="1" colspan="1">1.2 (16.8)</td><td rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Least-squares means (SE) change from baseline at Week 24</td><td align="left" rowspan="1" colspan="1">&#x02212;0.1 (0.8)</td><td align="left" rowspan="1" colspan="1">1.5 (0.8)</td><td rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Least-squares means difference (95% CI)</td><td align="left" colspan="2" rowspan="1">&#x02212;1.6 (&#x02212;3.8, 0.6)</td><td align="left" rowspan="1" colspan="1">0.1437</td></tr></tbody></table><table-wrap-foot><fn><p>ADCS-ADL-SIV, Alzheimer's Disease Cooperative Study&#x02013;Activities of Daily Living scale&#x02013;Severe Impairment Version; ADCS-CGIC, Alzheimer's Disease Cooperative Study&#x02013;Clinical Global Impression of Change; CI, confidence interval; N, number of patients with an assessment at the given time point; n, number of patients in a given category; NPI-12, 12-item Neuropsychiatric Inventory; SD, standard deviation; SE, standard error; SIB, Severe Impairment Battery.</p></fn></table-wrap-foot></table-wrap><fig id="fig02" position="float"><label>Figure 2</label><caption><p>Least-squares means change from baseline to Week 24 on (A) SIB and (B) ADCS-ADL-SIV (modified full analysis set). ADCS-ADL-SIV, Alzheimer's Disease Cooperative Study&#x02013;Activities of Daily Living scale&#x02013;Severe Impairment Version; SEM, standard error of the least-squares means; SIB, Severe Impairment Battery. Error bars represent the SEM. *<italic>P</italic>&#x000a0;&#x0003c;&#x000a0;0.05; **<italic>P</italic>&#x000a0;&#x0003c;&#x000a0;0.0001 versus 4.6&#x000a0;mg/24&#x000a0;h patch.</p></caption><graphic xlink:href="cns0019-0745-f2"/></fig><p>In both groups, the ADCS-ADL-SIV score decreased from baseline throughout the study. Significantly less deterioration was observed on the ADCS-ADL-SIV with 13.3&#x000a0;mg/24&#x000a0;h versus 4.6&#x000a0;mg/24&#x000a0;h patch at Weeks 16 (<italic>P</italic>&#x000a0;=&#x000a0;0.049; difference 1.0 point; 95% CI 0.0, 2.0) and 24 (primary endpoint; <italic>P</italic>&#x000a0;=&#x000a0;0.025; difference 1.2 points; 95% CI 0.2, 2.3; <xref ref-type="fig" rid="fig02">Figure 2</xref>B; <xref ref-type="table" rid="tbl2">Table 2</xref>). These findings were supported by the longitudinal (<italic>P</italic>&#x000a0;=&#x000a0;0.057; difference 1.0 point; 95% CI &#x02212;0.0, 2.1 at Week 16 and <italic>P</italic>&#x000a0;=&#x000a0;0.031; difference 1.3 points; 95% CI 0.1, 2.6 at Week 24) and sensitivity analyses (<italic>P</italic>&#x000a0;=&#x000a0;0.032; difference 1.3 points; 95% CI 0.1, 2.5 at Week 16 and <italic>P</italic>&#x000a0;=&#x000a0;0.016; difference 1.6 points; 95% CI 0.3, 3.0 at Week 24).</p></sec><sec><title>Secondary Outcome Analyses</title><p>The between-group difference in the distribution of ADCS-CGIC ratings was significant (<italic>P</italic>&#x000a0;=&#x000a0;0.0023; <xref ref-type="table" rid="tbl2">Table 2</xref>). A significantly higher percentage of patients receiving 13.3&#x000a0;mg/24&#x000a0;h compared with 4.6&#x000a0;mg/24&#x000a0;h patch displayed improvement in clinical status from baseline&#x02013;Week 24 (<italic>P</italic>&#x000a0;=&#x000a0;0.0094). There were no significant between-group differences at Week 24 on the NPI-12 (<xref ref-type="table" rid="tbl2">Table 2</xref>; <italic>P</italic>&#x000a0;=&#x000a0;0.1437; difference &#x02212;1.6 points; 95% CI &#x02212;3.8, 0.6).</p></sec><sec><title>Safety and Tolerability</title><p>Overall, the incidence of AEs was similar between the 13.3&#x000a0;mg/24&#x000a0;h and 4.6&#x000a0;mg/24&#x000a0;h patch groups (74.6% [n&#x000a0;=&#x000a0;265/355] vs. 73.3% [n&#x000a0;=&#x000a0;263/359], respectively; <xref ref-type="table" rid="tbl3">Table 3</xref>). By preferred term, most AEs were more frequent with 13.3&#x000a0;mg/24&#x000a0;h than 4.6&#x000a0;mg/24&#x000a0;h patch (<xref ref-type="table" rid="tbl3">Table 3</xref>), with the exception of agitation, urinary tract infection, application site dermatitis, anxiety, confusional state, constipation, hallucination, and peripheral edema.</p><table-wrap id="tbl3" position="float"><label>Table 3</label><caption><p>Most frequent AEs<xref ref-type="table-fn" rid="tf3-2"/> by treatment and preferred term in the 24-week treatment phase</p></caption><table frame="hsides" rules="groups"><thead><tr><th rowspan="1" colspan="1"/><th align="left" rowspan="1" colspan="1">13.3&#x000a0;mg/24&#x000a0;h rivastigmine patch N&#x000a0;=&#x000a0;355 n (%)</th><th align="left" rowspan="1" colspan="1">4.6&#x000a0;mg/24&#x000a0;h rivastigmine patch N&#x000a0;=&#x000a0;359 n (%)</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Any AE</td><td align="left" rowspan="1" colspan="1">265 (74.6)</td><td align="left" rowspan="1" colspan="1">263 (73.3)</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;Application site erythema</td><td align="left" rowspan="1" colspan="1">47 (13.2)</td><td align="left" rowspan="1" colspan="1">42 (11.7)</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;Agitation</td><td align="left" rowspan="1" colspan="1">41 (11.5)</td><td align="left" rowspan="1" colspan="1">51 (14.2)</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;Urinary tract infection</td><td align="left" rowspan="1" colspan="1">29 (8.2)</td><td align="left" rowspan="1" colspan="1">34 (9.5)</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;Application site dermatitis</td><td align="left" rowspan="1" colspan="1">27 (7.6)</td><td align="left" rowspan="1" colspan="1">33 (9.2)</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;Fall</td><td align="left" rowspan="1" colspan="1">27 (7.6)</td><td align="left" rowspan="1" colspan="1">21 (5.8)</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;Insomnia</td><td align="left" rowspan="1" colspan="1">25 (7.0)</td><td align="left" rowspan="1" colspan="1">15 (4.2)</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;Vomiting</td><td align="left" rowspan="1" colspan="1">25 (7.0)</td><td align="left" rowspan="1" colspan="1">9 (2.5)</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;Diarrhea</td><td align="left" rowspan="1" colspan="1">23 (6.5)</td><td align="left" rowspan="1" colspan="1">19 (5.3)</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;Weight decreased</td><td align="left" rowspan="1" colspan="1">23 (6.5)</td><td align="left" rowspan="1" colspan="1">11 (3.1)</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;Nausea</td><td align="left" rowspan="1" colspan="1">22 (6.2)</td><td align="left" rowspan="1" colspan="1">10 (2.8)</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;Depression</td><td align="left" rowspan="1" colspan="1">17 (4.8)</td><td align="left" rowspan="1" colspan="1">15 (4.2)</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;Decreased appetite</td><td align="left" rowspan="1" colspan="1">17 (4.8)</td><td align="left" rowspan="1" colspan="1">5 (1.4)</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;Anxiety</td><td align="left" rowspan="1" colspan="1">16 (4.5)</td><td align="left" rowspan="1" colspan="1">16 (4.5)</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;Hypertension</td><td align="left" rowspan="1" colspan="1">13 (3.7)</td><td align="left" rowspan="1" colspan="1">9 (2.5)</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;Application site pruritus</td><td align="left" rowspan="1" colspan="1">13 (3.7)</td><td align="left" rowspan="1" colspan="1">8 (2.2)</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;Confusional state</td><td align="left" rowspan="1" colspan="1">12 (3.4)</td><td align="left" rowspan="1" colspan="1">13 (3.6)</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;Somnolence</td><td align="left" rowspan="1" colspan="1">12 (3.4)</td><td align="left" rowspan="1" colspan="1">9 (2.5)</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;Constipation</td><td align="left" rowspan="1" colspan="1">11 (3.1)</td><td align="left" rowspan="1" colspan="1">12 (3.3)</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;Urinary incontinence</td><td align="left" rowspan="1" colspan="1">11 (3.1)</td><td align="left" rowspan="1" colspan="1">10 (2.8)</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;Application site irritation</td><td align="left" rowspan="1" colspan="1">11 (3.1)</td><td align="left" rowspan="1" colspan="1">9 (2.5)</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;Dehydration</td><td align="left" rowspan="1" colspan="1">11 (3.1)</td><td align="left" rowspan="1" colspan="1">8 (2.2)</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;Dizziness</td><td align="left" rowspan="1" colspan="1">11 (3.1)</td><td align="left" rowspan="1" colspan="1">5 (1.4)</td></tr></tbody></table><table-wrap-foot><fn><p>AE, adverse event; N, number of patients in the population; n, number of patients reporting AE.</p></fn><fn id="tf3-2"><p>Only AEs with a &#x02265;3% incidence in the 13.3&#x000a0;mg/24&#x000a0;h patch group are shown. A patient with multiple occurrences of an AE was counted only once in the AE category. AEs are presented by descending frequency in the 13.3&#x000a0;mg/24&#x000a0;h patch group.</p></fn></table-wrap-foot></table-wrap><p>Gastrointestinal AEs (nausea, vomiting, and diarrhea) were more frequent with 13.3&#x000a0;mg/24&#x000a0;h than 4.6&#x000a0;mg/24&#x000a0;h patch (nausea: 6.2% vs. 2.8%; vomiting 7.0% vs. 2.5%; diarrhea: 6.5% vs. 5.3%, respectively). Approximately a quarter of all patients experienced a skin irritation AE (26.5%, 13.3&#x000a0;mg/24&#x000a0;h patch; 24.0%, 4.6&#x000a0;mg/24&#x000a0;h patch).</p><p>The incidence of deaths during the study period and SAEs was comparable between the 13.3&#x000a0;mg/24&#x000a0;h and 4.6&#x000a0;mg/24&#x000a0;h patch groups (deaths: 0.3% in both groups; SAEs: 14.9% vs. 13.6%, respectively; <xref ref-type="table" rid="tbl4">Table 4</xref>). The deaths were not considered study-drug-related. SAEs were most commonly psychiatric disorders (3.1% and 4.2%, 13.3&#x000a0;mg/24&#x000a0;h and 4.6&#x000a0;mg/24&#x000a0;h patch group, respectively). Overall, 8.2% of the 13.3&#x000a0;mg/24&#x000a0;h and 4.5% of the 4.6&#x000a0;mg/24&#x000a0;h patch group discontinued due to SAEs. Discontinuations due to nonserious AEs (most commonly psychiatric disorders) were numerically higher with 13.3&#x000a0;mg/24&#x000a0;h (13.5%) than 4.6&#x000a0;mg/24&#x000a0;h patch (10.9%). Interestingly, discontinuations due to skin irritations at the application site were lower with 13.3&#x000a0;mg/24&#x000a0;h (1.7%) than 4.6&#x000a0;mg/24&#x000a0;h patch (2.5%; <xref ref-type="table" rid="tbl4">Table 4</xref>).</p><table-wrap id="tbl4" position="float"><label>Table 4</label><caption><p>The incidence of deaths, SAEs, and discontinuations due to AEs and SAEs (safety set)</p></caption><table frame="hsides" rules="groups"><thead><tr><th rowspan="1" colspan="1"/><th align="left" rowspan="1" colspan="1">13.3&#x000a0;mg/24&#x000a0;h rivastigmine patch N&#x000a0;=&#x000a0;355 n (%)</th><th align="left" rowspan="1" colspan="1">4.6&#x000a0;mg/24&#x000a0;h rivastigmine patch N&#x000a0;=&#x000a0;359 n (%)</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Deaths<xref ref-type="table-fn" rid="tf4-2"/></td><td align="left" rowspan="1" colspan="1">1 (0.3)</td><td align="left" rowspan="1" colspan="1">1 (0.3)</td></tr><tr><td align="left" rowspan="1" colspan="1">SAE(s)</td><td align="left" rowspan="1" colspan="1">53 (14.9)</td><td align="left" rowspan="1" colspan="1">49 (13.6)</td></tr><tr><td align="left" rowspan="1" colspan="1">Discontinuations due to SAE(s)</td><td align="left" rowspan="1" colspan="1">29 (8.2)</td><td align="left" rowspan="1" colspan="1">16 (4.5)</td></tr><tr><td align="left" rowspan="1" colspan="1">Discontinuations due to non-serious AE(s)</td><td align="left" rowspan="1" colspan="1">48 (13.5)</td><td align="left" rowspan="1" colspan="1">39 (10.9)</td></tr><tr><td align="left" rowspan="1" colspan="1">Discontinuations due to nausea or vomiting</td><td align="left" rowspan="1" colspan="1">9 (2.5)</td><td align="left" rowspan="1" colspan="1">4 (1.1)</td></tr><tr><td align="left" rowspan="1" colspan="1">Discontinuations due to skin irritations at the application site</td><td align="left" rowspan="1" colspan="1">6 (1.7)</td><td align="left" rowspan="1" colspan="1">9 (2.5)</td></tr></tbody></table><table-wrap-foot><fn><p>AE, adverse event; N, number of patients in the population; n, number of patients reporting AE; SAE, serious adverse event.</p></fn><fn id="tf4-2"><p>Deaths that occurred during the study period.</p></fn></table-wrap-foot></table-wrap><p>Three clinically notable vital sign abnormalities were reported as AEs. Two patients experienced weight gain, classed as nonserious, mild in severity, and not suspected to be study-drug-related. One patient had an increase in systolic blood pressure, which was nonserious, mild, and suspected to be study-drug-related.</p></sec></sec><sec sec-type="conclusions"><title>Conclusions</title><p>This was the first study to assess the efficacy, safety, and tolerability of 13.3&#x000a0;mg/24&#x000a0;h rivastigmine patch in patients with severe AD. As expected given the progressive nature of disease in this population, both treatment groups showed deterioration (SIB and ADCS-ADL-SIV) over the course of this 24-week study. However, 13.3&#x000a0;mg/24&#x000a0;h patch was associated with superior efficacy on the SIB and ADCS-ADL-SIV, compared with 4.6&#x000a0;mg/24&#x000a0;h patch at Weeks 16 and 24 (co-primary endpoint) in the primary last-observation-carried-forward analyses. Supporting the primary findings, 13.3&#x000a0;mg/24&#x000a0;h patch demonstrated efficacy on global function (ADCS-CGIC), providing evidence for clinical relevance of the high-dose treatment effects. Longitudinal and sensitivity analyses were also supportive of the primary findings. No significant differences were observed on behavior (NPI-12) or based on the similarity in incidence of psychiatric disorders as AEs between groups.</p><p>There tended to be a slight dose-related increase in incidence of specific AEs, including gastrointestinal-related (i.e., nausea, vomiting, decreased appetite, and weight loss), and application site erythema with 13.3&#x000a0;mg/24&#x000a0;h versus 4.6&#x000a0;mg/24&#x000a0;h patch. Yet, overall incidences of AEs were similar between groups suggesting that, generally, patients were able to tolerate higher doses without negatively impacting tolerability. Preliminary safety review of the 13.3&#x000a0;mg/24&#x000a0;h rivastigmine patch suggests a profile consistent with previous studies <xref rid="b9" ref-type="bibr">9</xref>.</p><p>The efficacy findings are supported by previous clinical trials, pooled, and retrospective analyses, which have suggested rivastigmine may benefit patients with moderately severe or severe AD <xref rid="b10" ref-type="bibr">10</xref>&#x02013;<xref rid="b12" ref-type="bibr">12</xref>,<xref rid="b21" ref-type="bibr">21</xref>&#x02013;<xref rid="b23" ref-type="bibr">23</xref>. A 26-week, randomized, controlled proof-of-concept trial of 3&#x02013;12&#x000a0;mg/day oral rivastigmine in moderately severe to severe AD demonstrated significant improvements versus placebo on the SIB (co-primary outcome measure) and ADCS-CGIC <xref rid="b12" ref-type="bibr">12</xref>, but did not reach significance on the NPI-10 (co-primary outcome measure), NPI-4 or ADCS-ADL <xref rid="b12" ref-type="bibr">12</xref>. In a study of 24&#x000a0;mg oral galantamine in severe AD, cognitive function (SIB) was significantly improved, but no significant treatment effects were observed on the Minimum Data Set-ADL scale (co-primary efficacy measures) <xref rid="b24" ref-type="bibr">24</xref>. Similarly, a study of 10&#x000a0;mg oral donepezil in severe AD demonstrated greater efficacy versus placebo on the SIB and Clinician's Interview-Based Impression of Change-Plus caregiver input (CIBIC-Plus; co-primary outcome measures), but not on ADCS-ADL-SIV or NPI <xref rid="b25" ref-type="bibr">25</xref>. A randomized, double-blind, 24-week study of 23&#x000a0;mg/day versus 10&#x000a0;mg/day oral donepezil in moderate-to-severe AD demonstrated significantly greater efficacy of the higher dose at Week 24 on the SIB <xref rid="b26" ref-type="bibr">26</xref>. No significant between-group differences were observed on the co-primary outcome measure, the CIBIC-Plus, or secondary efficacy measures (ADCS-ADL or MMSE) <xref rid="b26" ref-type="bibr">26</xref>.</p><p>This is the first study to demonstrate efficacy of higher-dose 13.3&#x000a0;mg/24&#x000a0;h rivastigmine patch on maintaining the ability to perform ADL, assessed as a co-primary outcome. In addition to cognition, benefits on ADL in severe disease stages are important, not only for patients, but also for caregivers because patients with severe AD are more dependent and require greater care than patients in earlier disease stages <xref rid="b27" ref-type="bibr">27</xref>,<xref rid="b28" ref-type="bibr">28</xref>. Dependency on others to perform ADL impacts patient quality of life <xref rid="b29" ref-type="bibr">29</xref>; minimizing functional decline could enhance quality of life and may decrease caregiver burden.</p><p>As the first study of rivastigmine patch in patients with severe AD, 4.6&#x000a0;mg/24&#x000a0;h patch was selected as a low-dose active comparator to fully evaluate high-dose patch in this patient population. Efficacy of 4.6&#x000a0;mg/24&#x000a0;h patch versus placebo has not been evaluated in a clinical trial setting; however, it was used as a titration dose in patients with mild-to-moderate AD during both the OPTIMA and <italic>I</italic>nvestigation of trans<italic>D</italic>ermal <italic>E</italic>xelon in <italic>AL</italic>zheimer's disease (IDEAL) studies <xref rid="b9" ref-type="bibr">9</xref>,<xref rid="b30" ref-type="bibr">30</xref>. The 4.6&#x000a0;mg/24&#x000a0;h patch provides comparable exposure to 3&#x000a0;mg twice daily <xref rid="b31" ref-type="bibr">31</xref>, an oral titration dose associated with proven efficacy <xref rid="b32" ref-type="bibr">32</xref>. Based on this comparison, it is conceivable that 4.6&#x000a0;mg/24&#x000a0;h patch could have masked the full extent of the 13.3&#x000a0;mg/24&#x000a0;h patch treatment effect in this trial. The 9.5&#x000a0;mg/24&#x000a0;h patch is currently the minimum effective dose and 13.3&#x000a0;mg/24&#x000a0;h patch the maximum effective dose for patients with mild-to-moderate AD, according to the US prescribing information <xref rid="b3" ref-type="bibr">3</xref>. Efficacy of 9.5&#x000a0;mg/24&#x000a0;h patch and the benefit:risk ratio of 9.5&#x000a0;mg/24&#x000a0;h versus 13.3&#x000a0;mg/24&#x000a0;h patch in patients with severe AD remains to be investigated in a clinical trial setting.</p><p>In summary, higher-dose 13.3&#x000a0;mg/24&#x000a0;h rivastigmine patch conferred benefits on cognition, ADL, and global functioning in patients with severe AD, without marked reduction in tolerability. These findings support previous data and suggest rivastigmine patch can benefit patients across the disease spectrum <xref rid="b9" ref-type="bibr">9</xref>,<xref rid="b30" ref-type="bibr">30</xref>. Based on the therapeutic benefit observed in this study population, the higher-dose rivastigmine patch is now approved in the USA for the symptomatic treatment of severe AD.</p></sec></body><back><ack><p>The ACTION principal investigators are acknowledged for their contributions to the study.</p><p>This study was funded by Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA. Medical writing and editorial assistance in the development of this manuscript were provided by Katy Cooke at Fishawack Communications Ltd, Abingdon, Oxon, UK, and this service was supported by Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA.</p></ack><sec><title>Conflict of Interest</title><p>This article has not been previously published, nor is it under consideration for publication elsewhere.</p><p>Martin Farlow has served as a paid consultant for Accera, Alltech, Astellas, Avanir, Bayer, Biogen, Bristol-Myers Squibb, Eisai Medical Research, GE Healthcare, Grifols, Helicon, INC Research, Medavante, Medivation Inc., Merck and Co. Inc., Novartis Pharma, Pfizer, Prana Biotech, QR Pharma, Sanofi Aventis Groupe, Schering-Plough, Eli Lilly, Shire Pharmaceuticals, and Toyama; is a paid speaker for Eisai, Forest, Novartis, Eli Lilly and Pfizer; and receives research support from Accera, Biogen, Eisai, Eli Lilly and Co., Genentech, Navidea, Novartis Pharma, and Roche. George Grossberg has served as a consultant for Accera, Baxter Bioscience, Forest Labs, Lundbeck, Novartis, Otsuka, and Takeda; has received research support from Accera, Baxter, Elan, Forest, Janssen, NIH, Novartis, Noven, and Pfizer; and serves on a safety monitoring board for Merck. Carl Sadowsky has served on advisory boards for Novartis, Accera and Lilly, and speakers' bureau for Novartis, Accera, Lilly and Pamlab. Xiangyi Meng and Monique Somogyi are full-time employees and stock holders of Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA.</p></sec><ref-list><title>References</title><ref id="b1"><label>1</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Perry</surname><given-names>EK</given-names></name><name><surname>Perry</surname><given-names>RH</given-names></name><name><surname>Blessed</surname><given-names>G</given-names></name><etal/></person-group><article-title>Changes in brain cholinesterases in senile dementia of Alzheimer type</article-title><source>Neuropathol Appl Neurobiol</source><year>1978</year><volume>4</volume><fpage>273</fpage><lpage>277</lpage><pub-id pub-id-type="pmid">703927</pub-id></element-citation></ref><ref id="b2"><label>2</label><element-citation publication-type="other"><collab>Exelon&#x000ae;</collab><year>2006</year><comment>US prescribing information. [online]. Available at: <ext-link ext-link-type="uri" xlink:href="http://www.accessdata.fda.gov/drugsatfda_docs/label/2006/020823s016,021025s008lbl.pdf">http://www.accessdata.fda.gov/drugsatfda_docs/label/2006/020823s016,021025s008lbl.pdf</ext-link>. (Accessed on 24 January 2013)</comment></element-citation></ref><ref id="b3"><label>3</label><element-citation publication-type="other"><collab>Exelon Patch&#x000ae;</collab><year>2009</year><comment>US Prescribing Information. Revised 2013. [online]. Available at: <ext-link ext-link-type="uri" xlink:href="http://www.pharma.us.novartis.com/product/pi/pdf/exelonpatch.pdf">http://www.pharma.us.novartis.com/product/pi/pdf/exelonpatch.pdf</ext-link>. (Accessed on 24 January 2013)</comment></element-citation></ref><ref id="b4"><label>4</label><element-citation publication-type="other"><collab>ARICEPT</collab><year>2010</year><comment>Prescribing Information. [online]. Available at: <ext-link ext-link-type="uri" xlink:href="http://www.aricept.com/assets/pdf/AriceptComboFullPINovember2010.pdf">http://www.aricept.com/assets/pdf/AriceptComboFullPINovember2010.pdf</ext-link>. (Accessed on 24 January 2013)</comment></element-citation></ref><ref id="b5"><label>5</label><element-citation publication-type="other"><collab>Galantamine (Razadyne ER&#x000ae;</collab><comment>Prescribing information. [online]. Available at: <ext-link ext-link-type="uri" xlink:href="http://www.accessdata.fda.gov/drugsatfda_docs/label/2004/021615lbl.pdf">http://www.accessdata.fda.gov/drugsatfda_docs/label/2004/021615lbl.pdf</ext-link>. (Accessed on 24 January 2013)</comment></element-citation></ref><ref id="b6"><label>6</label><element-citation publication-type="other"><collab>Namenda US</collab><year>2011</year><comment>Prescribing Information. [online]. Available at: <ext-link ext-link-type="uri" xlink:href="http://www.frx.com/pi/namenda_pi.pdf">http://www.frx.com/pi/namenda_pi.pdf</ext-link>. (Accessed on 24 January 2013)</comment></element-citation></ref><ref id="b7"><label>7</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Grossberg</surname><given-names>GT</given-names></name><name><surname>Olin</surname><given-names>JT</given-names></name><name><surname>Somogyi</surname><given-names>M</given-names></name><etal/></person-group><article-title>Dose effects associated with rivastigmine transdermal patch in patients with mild-to-moderate Alzheimer's disease</article-title><source>Int J Clin Pract</source><year>2011</year><volume>65</volume><fpage>465</fpage><lpage>471</lpage><pub-id pub-id-type="pmid">21309961</pub-id></element-citation></ref><ref id="b8"><label>8</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Anand</surname><given-names>R</given-names></name><name><surname>Messina</surname><given-names>J</given-names></name><name><surname>Hartman</surname><given-names>R</given-names></name></person-group><article-title>Dose-response effect of rivastigmine in the treatment of Alzheimer's disease</article-title><source>Int J Geriatr Psychopharmacol</source><year>2000</year><volume>2</volume><fpage>68</fpage><lpage>72</lpage></element-citation></ref><ref id="b9"><label>9</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cummings</surname><given-names>J</given-names></name><name><surname>Froelich</surname><given-names>L</given-names></name><name><surname>Black</surname><given-names>SE</given-names></name><etal/></person-group><article-title>Randomized, double-blind, parallel-group, 48-week study for efficacy and safety of a higher-dose rivastigmine patch (15 vs. 10&#x000a0;cm<sup>2</sup>) in Alzheimer's disease</article-title><source>Dement Geriatr Cogn Disord</source><year>2012</year><volume>33</volume><fpage>341</fpage><lpage>353</lpage><pub-id pub-id-type="pmid">22796905</pub-id></element-citation></ref><ref id="b10"><label>10</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Burns</surname><given-names>A</given-names></name><name><surname>Spiegel</surname><given-names>R</given-names></name><name><surname>Quarg</surname><given-names>P</given-names></name></person-group><article-title>Efficacy of rivastigmine in subjects with moderately severe Alzheimer's disease</article-title><source>Int J Geriatr Psychiatry</source><year>2004</year><volume>19</volume><fpage>243</fpage><lpage>249</lpage><pub-id pub-id-type="pmid">15027039</pub-id></element-citation></ref><ref id="b11"><label>11</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kurz</surname><given-names>A</given-names></name><name><surname>Farlow</surname><given-names>M</given-names></name><name><surname>Quarg</surname><given-names>P</given-names></name><etal/></person-group><article-title>Disease stage in Alzheimer disease and treatment effects of rivastigmine</article-title><source>Alzheimer Dis Assoc Disord</source><year>2004</year><volume>18</volume><fpage>123</fpage><lpage>128</lpage><pub-id pub-id-type="pmid">15494617</pub-id></element-citation></ref><ref id="b12"><label>12</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lopez-Pousa</surname><given-names>S</given-names></name><name><surname>Vilalta-Franch</surname><given-names>J</given-names></name><name><surname>Hermandez</surname><given-names>B</given-names></name><etal/></person-group><article-title>Efficacy of rivastigmine in patients with severe Alzheimer's Disease: A double-blind, randomized pilot study</article-title><source>Brain Aging</source><year>2004</year><volume>4</volume><fpage>26</fpage><lpage>34</lpage></element-citation></ref><ref id="b13"><label>13</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>McKhann</surname><given-names>G</given-names></name><name><surname>Drachman</surname><given-names>D</given-names></name><name><surname>Folstein</surname><given-names>M</given-names></name><etal/></person-group><article-title>Clinical diagnosis of Alzheimer disease: Report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's disease</article-title><source>Neurology</source><year>1984</year><volume>34</volume><fpage>939</fpage><lpage>944</lpage><pub-id pub-id-type="pmid">6610841</pub-id></element-citation></ref><ref id="b14"><label>14</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Folstein</surname><given-names>MF</given-names></name><name><surname>Folstein</surname><given-names>SE</given-names></name><name><surname>McHugh</surname><given-names>PR</given-names></name></person-group><article-title>&#x0201c;Mini-mental state&#x0201d;. A practical method for grading the cognitive state of patients for the clinician</article-title><source>J Psychiatr Res</source><year>1975</year><volume>12</volume><fpage>189</fpage><lpage>198</lpage><pub-id pub-id-type="pmid">1202204</pub-id></element-citation></ref><ref id="b15"><label>15</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Farlow</surname><given-names>MR</given-names></name><name><surname>Grossberg</surname><given-names>G</given-names></name><name><surname>Gauthier</surname><given-names>S</given-names></name><etal/></person-group><article-title>The ACTION study: Methodology of a trial to evaluate safety and efficacy of a higher dose rivastigmine transdermal patch in severe Alzheimer's disease</article-title><source>Curr Med Res Opin</source><year>2010</year><volume>26</volume><fpage>2441</fpage><lpage>2447</lpage><pub-id pub-id-type="pmid">20828359</pub-id></element-citation></ref><ref id="b16"><label>16</label><element-citation publication-type="book"><collab>American Psychiatric Association</collab><source>Diagnostic and statistical manual of mental disorders (DSM-IV)</source><year>1994</year><edition>4th edn</edition><publisher-loc>Washington, DC</publisher-loc><publisher-name>American Psychiatric Association</publisher-name></element-citation></ref><ref id="b17"><label>17</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Saxton</surname><given-names>J</given-names></name><name><surname>McGonigle-Gibson</surname><given-names>K</given-names></name><name><surname>Swihart</surname><given-names>A</given-names></name><etal/></person-group><article-title>Assessment of the severely impaired patient: Description and validation of a new neuropsychological test battery</article-title><source>Psychol Assess</source><year>1990</year><volume>2</volume><fpage>298</fpage><lpage>303</lpage></element-citation></ref><ref id="b18"><label>18</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Galasko</surname><given-names>D</given-names></name><name><surname>Bennett</surname><given-names>D</given-names></name><name><surname>Sano</surname><given-names>M</given-names></name><etal/></person-group><article-title>An inventory to assess activities of daily living for clinical trials in Alzheimer's disease. The Alzheimer's Disease Cooperative Study</article-title><source>Alzheimer Dis Assoc Disord</source><year>1997</year><volume>11</volume><issue>Suppl 2</issue><fpage>S33</fpage><lpage>S39</lpage><pub-id pub-id-type="pmid">9236950</pub-id></element-citation></ref><ref id="b19"><label>19</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schneider</surname><given-names>LS</given-names></name><name><surname>Olin</surname><given-names>JT</given-names></name><name><surname>Doody</surname><given-names>RS</given-names></name><etal/></person-group><article-title>Validity and reliability of the Alzheimer's Disease Cooperative Study-Clinical Global Impression of Change. The Alzheimer's Disease Cooperative Study</article-title><source>Alzheimer Dis Assoc Disord</source><year>1997</year><volume>11</volume><issue>Suppl 2</issue><fpage>S22</fpage><lpage>S32</lpage><pub-id pub-id-type="pmid">9236949</pub-id></element-citation></ref><ref id="b20"><label>20</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cummings</surname><given-names>JL</given-names></name><name><surname>Mega</surname><given-names>M</given-names></name><name><surname>Gray</surname><given-names>K</given-names></name><etal/></person-group><article-title>The Neuropsychiatric Inventory: Comprehensive assessment of psychopathology in dementia</article-title><source>Neurology</source><year>1994</year><volume>44</volume><fpage>2308</fpage><lpage>2314</lpage><pub-id pub-id-type="pmid">7991117</pub-id></element-citation></ref><ref id="b21"><label>21</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Farlow</surname><given-names>MR</given-names></name><name><surname>Grossberg</surname><given-names>GT</given-names></name><name><surname>Meng</surname><given-names>X</given-names></name><etal/></person-group><article-title>Rivastigmine transdermal patch and capsule in Alzheimer's disease: Influence of disease stage on response to therapy</article-title><source>Int J Geriatr Psychiatry</source><year>2011</year><volume>26</volume><fpage>1236</fpage><lpage>1243</lpage><pub-id pub-id-type="pmid">22068922</pub-id></element-citation></ref><ref id="b22"><label>22</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Doraiswamy</surname><given-names>PM</given-names></name><name><surname>Krishnan</surname><given-names>KR</given-names></name><name><surname>Anand</surname><given-names>R</given-names></name><etal/></person-group><article-title>Long-term effects of rivastigmine in moderately severe Alzheimer's disease: Does early initiation of therapy offer sustained benefits?</article-title><source>Prog Neuropsychopharmacol Biol Psychiatry</source><year>2002</year><volume>26</volume><fpage>705</fpage><lpage>712</lpage><pub-id pub-id-type="pmid">12188103</pub-id></element-citation></ref><ref id="b23"><label>23</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Karaman</surname><given-names>Y</given-names></name><name><surname>Erdogan</surname><given-names>F</given-names></name><name><surname>Koseoglu</surname><given-names>E</given-names></name><etal/></person-group><article-title>A 12-month study of the efficacy of rivastigmine in patients with advanced moderate Alzheimer's disease</article-title><source>Dement Geriatr Cogn Disord</source><year>2005</year><volume>19</volume><fpage>51</fpage><lpage>56</lpage><pub-id pub-id-type="pmid">15383747</pub-id></element-citation></ref><ref id="b24"><label>24</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Burns</surname><given-names>A</given-names></name><name><surname>Bernabei</surname><given-names>R</given-names></name><name><surname>Bullock</surname><given-names>R</given-names></name><etal/></person-group><article-title>Safety and efficacy of galantamine (Reminyl) in severe Alzheimer's disease (the SERAD study): A randomised, placebo-controlled, double-blind trial</article-title><source>Lancet Neurol</source><year>2009</year><volume>8</volume><fpage>39</fpage><lpage>47</lpage><pub-id pub-id-type="pmid">19042161</pub-id></element-citation></ref><ref id="b25"><label>25</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Black</surname><given-names>SE</given-names></name><name><surname>Doody</surname><given-names>R</given-names></name><name><surname>Li</surname><given-names>H</given-names></name><etal/></person-group><article-title>Donepezil preserves cognition and global function in patients with severe Alzheimer disease</article-title><source>Neurology</source><year>2007</year><volume>69</volume><fpage>459</fpage><lpage>469</lpage><pub-id pub-id-type="pmid">17664405</pub-id></element-citation></ref><ref id="b26"><label>26</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Farlow</surname><given-names>MR</given-names></name><name><surname>Salloway</surname><given-names>S</given-names></name><name><surname>Tariot</surname><given-names>PN</given-names></name><etal/></person-group><article-title>Effectiveness and tolerability of high-dose (23&#x000a0;mg/d) versus standard-dose (10&#x000a0;mg/d) donepezil in moderate to severe Alzheimer's disease: A 24-week, randomized, double-blind study</article-title><source>Clin Ther</source><year>2010</year><volume>32</volume><fpage>1234</fpage><lpage>1251</lpage><pub-id pub-id-type="pmid">20678673</pub-id></element-citation></ref><ref id="b27"><label>27</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Herrmann</surname><given-names>N</given-names></name><name><surname>Gauthier</surname><given-names>S</given-names></name></person-group><article-title>Diagnosis and treatment of dementia: 6. Management of severe Alzheimer disease</article-title><source>CMAJ</source><year>2008</year><volume>179</volume><fpage>1279</fpage><lpage>1287</lpage><pub-id pub-id-type="pmid">19047609</pub-id></element-citation></ref><ref id="b28"><label>28</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mohamed</surname><given-names>S</given-names></name><name><surname>Rosenheck</surname><given-names>R</given-names></name><name><surname>Lyketsos</surname><given-names>CG</given-names></name><etal/></person-group><article-title>Caregiver burden in Alzheimer disease: Cross-sectional and longitudinal patient correlates</article-title><source>Am J Geriatr Psychiatry</source><year>2010</year><volume>18</volume><fpage>917</fpage><lpage>927</lpage><pub-id pub-id-type="pmid">20808108</pub-id></element-citation></ref><ref id="b29"><label>29</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Andersen</surname><given-names>CK</given-names></name><name><surname>Wittrup-Jensen</surname><given-names>KU</given-names></name><name><surname>Lolk</surname><given-names>A</given-names></name><etal/></person-group><article-title>Ability to perform activities of daily living is the main factor affecting quality of life in patients with dementia</article-title><source>Health and Qual Life Outcomes</source><year>2004</year><volume>2</volume><fpage>52</fpage></element-citation></ref><ref id="b30"><label>30</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Winblad</surname><given-names>B</given-names></name><name><surname>Cummings</surname><given-names>J</given-names></name><name><surname>Andreasen</surname><given-names>N</given-names></name><etal/></person-group><article-title>A six-month double-blind, randomized, placebo-controlled study of a transdermal patch in Alzheimer's disease &#x02013; rivastigmine patch <italic>versus</italic> capsule</article-title><source>Int J Geriatr Psychiatry</source><year>2007</year><volume>22</volume><fpage>456</fpage><lpage>467</lpage><pub-id pub-id-type="pmid">17380489</pub-id></element-citation></ref><ref id="b31"><label>31</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mercier</surname><given-names>F</given-names></name><name><surname>Lef&#x000e8;vre</surname><given-names>G</given-names></name><name><surname>Huang</surname><given-names>HL</given-names></name><etal/></person-group><article-title>Rivastigmine exposure provided by a transdermal patch <italic>versus</italic> capsules</article-title><source>Curr Med Res Opin</source><year>2007</year><volume>23</volume><fpage>3199</fpage><lpage>3204</lpage><pub-id pub-id-type="pmid">18001519</pub-id></element-citation></ref><ref id="b32"><label>32</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Agid</surname><given-names>Y</given-names></name><name><surname>Dubois</surname><given-names>B</given-names></name><name><surname>Investigators</surname><given-names>IR</given-names></name><etal/></person-group><article-title>Efficacy and tolerability of rivastigmine in patients with dementia of the Alzheimer type</article-title><source>Curr Ther Res</source><year>1998</year><volume>59</volume><fpage>837</fpage><lpage>845</lpage></element-citation></ref></ref-list></back></article>